Aggressive systemic mastocytosis and related mast cell disorders: Current treatment options and proposed response criteria

Leukemia Research

Volumn 27, Issue 7, 2003, Pages 635-641

  Valent, Peter ^a   Akin, Cem ^b   Sperr, Wolfgang R ^a   Escribano, Luis ^c   Arock, Michel ^d   Horny, Hans Peter ^e   Bennett, John M ^f   Metcalfe, Dean D ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d Faculte de Pharmacie   (France)

^e UNIVERSITY OF LÜBECK   (Germany)

^f UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Aggressive systematic mastocytosis; Classification; Interferon ; Response criteria; Therapy

Indexed keywords

ALPHA INTERFERON; GLUCOCORTICOID;

ANEMIA; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; HEPATOMEGALY; HUMAN; HYPERSPLENISM; HYPOALBUMINEMIA; MALABSORPTION; MAST CELL; MASTOCYTOSIS; OSTEOPOROSIS; PORTAL HYPERTENSION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 0345772088     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00168-6     Document Type: Article

References (51)

1. Lennert K., Parwaresch M.R. Mast cells and mast cell neoplasia: a review. Histopathology. 3:1979;349-365.
2. Metcalfe D.D. Classification and diagnosis of mastocytosis: current status. J. Invest. Dermatol. 96:1991;2S-4S.
3. Valent P. Biology, classification and treatment of human mastocytosis. Wien. Klin. Wschr. 108:1996;385-397.
4. Travis W.D., Li C.Y., Bergstralh E.J., Yam L.T., Swee R.G. Systemic mast cell disease. Analysis of 58 cases and literature review. Medicine. 67:1988;345-368.
5. Horan R.F., Austen K.F. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J. Invest. Dermatol. 96:1991;5S-13S.
6. Longley B.J., Tyrrell L., Lu S.Z., Ma Y.S., Langley K., Ding T.G., Duffy T.et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat. Genet. 12:1996;312-314.
7. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y.et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc. Natl. Acad. Sci. U.S.A. 92:1995;10560-10564.
8. Longley B.J., Metcalfe D.D., Tharp M., Wang X., Tyrrell L., Lu S.Z.et al. Activating and dominant inactivating c-kit catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc. Natl. Acad. Sci. U.S.A. 96:1999;1609-1614.
9. Akin C., Kirshenbaum A.S., Semere T., Worobec A.S., Scott L.M., Metcalfe D.D. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp. Hematol. 28:2000;140-147.
10. Yavuz A.S., Lipsky P.E., Yavuz S., Metcalfe D.D., Akin C. Evidence for the involvement of an hematopoietic progenitor cell in systemic mastocytosis from single cell analysis of mutations in the c-kit gene. Blood. 100:2002;661-665.
11. Lawrence J.B., Friedman B.S., Travis W.D., Chinchilli V.M., Metcalfe D.D., Gralnick H.R. Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis. Am. J. Med. 91:1991;612-624.
12. Travis W.D., Li C.Y., Yam L.T., Bergstralh E.J., Swee R.G. Significance of systemic mast cell disease with associated hematologic disorders. Cancer. 62:1988;965-972.
13. Horny H.-P., Ruck M., Wehrmann M., Kaiserling E. Blood findings in generalized mastocytosis: evidence of frequent simultaneous occurrence of myeloproliferative disorders. Br. J. Haematol. 76:1990;186-193.
14. Valent P., Horny H.-P., Escribano L., Longley B.J., Li C.Y., Schwartz L.B.et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk. Res. 25:2001;603-625.
15. Reisberg I.R., Oyakawa S. Mastocytosis with malabsorption, myelofibrosis, and massive ascites. Am. J. Gastroenterol. 82:1987;54-60.
16. Mican J.M., Di-Bisceglie A.M., Fong T.L., Travis W.D., Kleiner D.E., Baker B.et al. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology. 22:1995;1163-1170.
17. Kyriakou D., Kouroumalis E., Konsolas J., Oekonomaki H., Tzardi M., Kanavaros P.et al. Systemic mastocytosis: a rare cause of noncirrhotic portal hypertension simulating autoimmune cholangitis - report of four cases. Am. J. Gastroenterol. 93:1998;106-108.
18. Rafii M., Firooznia H., Golimbu C., Balthazar E. Pathologic fracture in systemic mastocytosis radiographic spectrum and review of the literature. Clin. Orthop. 180:1983;260-267.
19. Roth J., Brudler O., Henze E. Functional asplenia in malignant mastocytosis. J. Nucl. Med. 26:1985;1149-1152.
20. Floman Y., Amir G. Systemic mastocytosis presenting with severe spinal osteopenia and multiple compression fractures. J. Spinal Disord. 4:1991;369-373.
21. Kimura A., Tanaka R., Taketomi Y., Dohi H., Fujimura K., Kamada N.et al. A case of mastocytoma with leukemic manifestation of its immature form in the terminal stage. Rinsho Ketsueki. 20:1979;1137-1146.
22. Escribano L., Orfao A., Villarrubia J., Martin F., Madruga J.I., Cuevas M.et al. Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemi. Cytometry. 30:1997;98-102.
23. Worobec A.S. Treatment of systemic mast cell disorders. Hematol. Oncol. North Am. 14:2000;659-687.
24. Worobec A.S., Metcalfe D.D. Mastocytosis: current treatment concepts. Int. Arch. Allergy Immunol. 127:2002;153-155.
25. Worobec A.S., Kirshenbaum A.S., Schwartz L.B., Metcalfe D.D. Treatment of Three Patients with Systemic Mastocytosis with Interferon Alpha-2b. Leuk. Lymphoma. 22:1996;501-508.
26. Kluin-Nelemans H.C., Jansen J.H., Breukelman H., Wolthers B.G., Kluin P.M.et al. Response to interferon alfa-2b in a patient with systemic mastocytosis. N. Engl. J. Med. 326:1992;619-623.
27. Lehmann T., Beyeler C., Lammle B., Hunziker T., Vock P., Olah A.J.et al. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alpha-2B. Br. J. Rheumatol. 35:1996;898-900.
28. Jost E., Michaux L., Vanden Abeele M., Boland B., Latinne D., Godfraind C.et al. Complex karyotype and absence of mutation in the c-kit receptor in aggressive mastocytosis presenting with pelvic osteolysis. Ann. Hematol. 80:2001;302-307.
29. Weide R., Ehlenz K., Lorenz W., Walthers E., Klausmann M., Pfluger K.H. Successful treatment of osteoporosis in systemic mastocytosis with interferon alpha-2b. Ann. Hematol. 72:1996;41-43.
30. Butterfield J.H. Response of severe systemic mastocytosis to interferon alpha. Br. J. Dermatol. 138:1998;489-495.
31. Fiehn C., Prummer O., Gallati H., Heilig B., Hunstein W. Treatment of systemic mastocytosis with interferon-gamma: failure after appearance of anti-IFN-gamma antibodies. Eur. J. Clin. Invest. 25:1995;615-618.
32. Pulik M., Lionnet F., Petit A., Genet P., Gaulier A. Long-term response to interferon-alpha in a patient with systemic mastocytosis and chronic myelomonocytic leukemia. Am. J. Hematol. 47:1994;66.
33. Chosidow O., Becherel P.A., Piette J.C., Arock M., Debre P., Frances C. Tripe palms associated with systemic mastocytosis: the role of transforming growth factor-alpha and efficacy of interferon-alfa. Br. J. Dermatol. 138:1998;698-703.
34. Krahl J., Baldauf P., Stoermer D. Systemische konnatale Mastozytose mit universeller Hautbeteiligung. Hautarzt. 50:1999;893-896.
35. Tefferi A., Li C.Y., Butterfield J.H., Hoagland H.C. Treatment of systemic mast-cell disease with cladribine. N. Engl. J. Med. 344:2001;307-309.
36. Delaporte E., Pierard E., Wolters B.G., Desreumaux P., Janin A., Cortot A.et al. Interferon-alpha in combination with corticosteroids improves systemic mast cell disease. Br. J. Dermatol. 132:1995;479-482.
37. Akin C., Scott L.M., Metcalfe D.D. Slowly progressive systemic mastocytosis with high mast cell burden and no evidence of a non-mast cell hematologic disorder. An example of a smoldering case? Leuk. Res. 25:2001;635-638.
38. Jordan J.H., Fritsche-Polanz R., Sperr W.R., Mitterbauer G., Födinger M., Schernthaner G.H.et al. A case of smouldering mastocytosis with high mast cell burden, monoclonal myeloid cells, and c-kit mutation Asp-816-Val. Leuk. Res. 25:2001;627-634.
39. Hauswirth A., Sperr W.R., Jordan J.-H., Ghannadan M., Schernthaner G.-H., Lechner K.et al. A case of smouldering mastocytosis with lymphadenopathy and eosinophilia. Leuk. Res. 26:2002;601-606.
40. Sotlar K., Marafioti T., Griesser H., Theil J., Aepinus C., Jaussi R.et al. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. Mol. Pathol. 53:2000;188-193.
41. Valent P., Akin C., Sperr W.R., Horny H.-P., Metcalfe D.D. Smouldering mastocytosis: a new type of systemic mastocytosis with slow progression. Int. Arch. Allergy Immunol. 127:2002;137-139.
42. Travis W.D., Li C.Y., Hoagland H.C., Travis L.B., Banks P.M. Mast cell leukemia: report of a case and review of the literature. Mayo. Clin. Proc. 61:1986;957-966.
43. Sperr W.R., Horny H.-P., Lechner K., Valent P. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk. Lymph. 37:2000;473-486.
44. Schwartz L.B., Sakai K., Bradford T.R., Ren S., Zweiman B., Worobec A.S.et al. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J. Clin. Invest. 96:1995;2702-2710.
45. Schwartz L.B., Metcalfe D.D., Miller J.S., Earl H., Sullivan T. Tryptase levels as an indicator of mast-cell activation in systemic anaphylaxis and mastocytosis. N. Engl. J. Med. 316:1987;1622-1626.
46. Horny H.-P., Sillaber C., Menke D., Kaiserling E., Wehrmann M., Stehberger B.et al. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am. J. Surg. Pathol. 22:1998;1132-1140.
47. Akin C., Schwartz L.B., Kitoh T., Obayashi H., Worobec A.S., Scott L.M.et al. Soluble stem cell factor receptor (CD117) and IL-2 receptor alpha chain (CD25) levels in the plasma of patients with mastocytosis: relationships to disease severity and bone marrow pathology. Blood. 96:2000;1267-1273.
48. Akin C., Metcalfe D.D. Surrogate markers of disease in mastocytosis. Int. Arch. Allergy Immunol. 127:2002;133-136.
49. Escribano L., Díaz-Agustín B., Bellas C., Navalón R., Nuñez R., Sperr W.R.et al. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk. Res. 25:2001;563-570.
50. Escribano L., Pérez de Oteyza J., Núnez R., Orfao A. Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis: report of a case of mastocytosis associated with a lymphoplasmocytic lymphoma. Leuk. Res. 26:2002;1043-1046.
51. Parker R.I. Hematologic aspects of mastocytosis II management of hematologic disorders in association with systemic mast cell disease. J. Invest. Dermatol. 96:1991;52S-53S.